Merck/Schering-Plough Zetia NDA
Executive Summary
Merck/Schering-Plough joint venture files NDA Dec. 27 for Zetia (ezetimibe) tablets for the reduction of elevated cholesterol. "Zetia is the first medicine to be submitted to the FDA for approval by Merck/Schering-Plough Pharmaceuticals," the joint venture notes. The product will be supported by three sales forces (1"The Pink Sheet" Dec. 17, 2001, p. 11)...
You may also be interested in...
Merck/Schering Zetia (Ezetimibe) Will Be Supported By Three Sales Forces
Merck will follow the Zocor model in launching Zetia (ezetimibe) into the cholesterol-lowering class by relying on separate sales forces and a co-promotion partner to establish the new product
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.